HFA Icon

What's Instore For Big Pharma In 2017?

HFA Padded
Rupert Hargreaves
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

What’s Instore For Big Pharma In 2017?

The US pharmaceutical industry has had a tough 2016, and according to Morgan Stanley, the outlook for the sector is no better next year.

Indeed, according to a lengthy report on the state of the pharmaceutical industry from Morgan, there are few catalysts for the sector’s growth next year and thanks to this the industry will be at the mercy of political decisions.

Due to election concerns and president-elect Trump’s comments about high drug prices, US major pharmaceuticals have underperformed the S&P...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for Hedge Fund Alpha